Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Aug 6, 2021 - Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium

Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium

Aug 6, 2021

Glenmark Life Sciences made a market debut with its shares getting listed at a 4% premium over issue price of Rs 720 per share on the bourses.

Its disappointing listing comes in the backdrop of an initial public offer (IPO) frenzy wherein many issues are getting listed on the bourses at steep premium.

The stock opened at Rs 750 on the NSE and at Rs 751 on the BSE.

Post listing, the market capitalisation of the company stood at Rs 92.7 bn, according to BSE data.

Many market analysts had assigned a subscribe rating to the issue considering the business growth outlook and almost stable operating margins.

Glenmark Life Sciences is a subsidiary of Glenmark Pharmaceuticals.

In 2019, the active pharmaceutical ingredients (API) manufacturing business of Glenmark was spun off into Glenmark Life Sciences as part of a broader reorganisation focusing on the API business.

--- Advertisement ---
Automobile Sector's Colossal Disruption Could Make You a Fortune

During any major disruption in a sector, fortunes are created.

And now, we are at the cusp of a major disruption that the automotive sector will experience.

It is the electric vehicles gold rush.

At Equitymaster, we have unearthed a hidden way to ride the 15x EV opportunity so that you could take home potentially life-changing gains in the long run.

You can get all details of the hidden way in our upcoming special online event.

YES, Register Me for FREE
------------------------------

Glenmark Life Sciences received good response from investors

The IPO saw strong demand from investors on the last day of the bidding process as the issue size was subscribed 45.08 times on the last day.

The public offer received bids for 663.3 m equity shares against the IPO size of 14 m equity shares.

The portion reserved for qualified institutional buyers (QIBs) was subscribed 36.97 times.

The non-institutional investors' quota received bids for 122.54 times, while the retail individual investors (RIIs) portion was subscribed 14.63 times.

The Rs 15.1 bn IPO by this API maker was sold from 27 July to 29 July.

Utilisation of funds raised through public issue

The company intends to use the proceeds from the public issue for the payment of outstanding purchase considerations to the promoter for the spin-off of the API business from the promoter and into the company.

It also aims to use it to fund capital expenditure requirements which includes the expansion of capacity at the Dahej (Gujarat) manufacturing site to meet the anticipated future demand of its generic API products.

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth

Company with good financials

The company has posted growth in its top and bottom lines for the last three fiscals.

For the financial year of 2021, Glenmark Life reported a profit of Rs 3.5 bn as well as a revenue of Rs 18.9 bn for the same year.

In the previous financial of 2020, it had a lower profit margin of Rs 3.1 bn upon the revenue of Rs 15.4 bn.

This marks an upward trend in profits and revenue with the latest financial year marking the highest in returns.

(Rs bn) FY19 FY20 Dec-20
Revenues 8.9 15.4 14.2
Revenue Growth (%)   73%  
Expenses 6.6 11.3 10.9
Profit Before Tax (PBT) 2.3 4.2 3.3
Net Profit 2 3.1 2.5
Data Source: Company's Red Herring Prospectus

The company has not declared or paid any dividend during the three immediately preceding financial years and until the date of filing of this red herring prospectus.

GLS will adopt a prudent dividend policy post listing based on its financial performance and future prospects.

Overview of Glenmark Life Sciences' product portfolio

GLS is a leading developer and manufacturer of high value, non-commoditised APIs.

Its portfolio comprises of 120 products (10 in laboratory development; 4 in laboratory validation and 106 being commercialised) across cardiovascular, CNS, diabetes, anti-infectives, and others.

The total market size for the 120 products globally, was estimated to be around US$140 bn in 2020 and is expected to grow by about 4.3% over the next five years to reach to about US$180 bn by 2026.

The future growth of these products is expected to remain stable driven by the rising prevalence of non-communicable diseases, growing demand from the regulated markets for drugs indicated for hypertension, diabetes and cancer, and ageing population.

--- Advertisement ---
3 "Super Smallcaps" You Didn't Know About

You may not have heard of these 3 "super smallcaps" ever before...

The mainstream press doesn't cover them... Most brokers don't know about them either...

Stocks like these 3 "super smallcaps" only come to your notice when they have rallied by hundreds or even thousands of percent... and are all over the news!

Richa revealed it all during her Super Smallcaps Summit

If you missed this event for some reason, then you can watch the special replay of this event.

Click Here to Watch the Replay...
------------------------------

Glenmark Life Sciences IPO grey market premium ahead of listing

According to market observers, Glenmark Life Sciences IPO's grey market premium (GMP) was Rs 85 on Thursday, which was Rs 80 on Wednesday, Rs 85 on Tuesday and Rs 90 on Monday respectively.

The slide in GMP post-closure of bidding was expected but not to this extent.

Even though, the company got listed at 4% premium to its issue price, the market remains optimistic about the company's performance going ahead.

About Glenmark Life Sciences

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of active pharmaceutical ingredients (APIs).

The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

It further operates in contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also exported to multiple countries such as Europe, North America, Latin America, Japan, etc.

Currently, it has 4 manufacturing facilities at Ankleshwar & Dahej in Gujarat and Mohol & Kurkumbh in Maharashtra with an aggregate annual installed capacity of 725.8 KL as of 31 December 2020.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Glenmark Life Sciences Makes Lacklustre Debut. Shares List At 4% Premium". Click here!

  

More Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

A Complete Guide for Beginners on How to Invest in IPOs

As an investor, you must have endeavoured to find a suitable opportunity for investing in IPOs. But do you know what is an IP...

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK LIFE SCIENCES SHARE PRICE


Dec 1, 2021 (Close)

TRACK GLENMARK LIFE SCIENCES

  • Track your investment in GLENMARK LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK LIFE SCIENCES

GLENMARK LIFE SCIENCES - ADCOCK INGRAM COMPARISON

COMPARE GLENMARK LIFE SCIENCES WITH

MARKET STATS